By: Forbes Real Time
February 06, 2013 at 07:31 AM EST
Biogen To Buy Elan's Tysabri Rights For $3.25 Billion
Biogen Idec will purchase all rights to the blockbuster multiple sclerosis drug Tysabri from its partner, Elan Pharmaceuticals, for $3.25 billion, adding a capstone to a long and tangled journey for a drug that was once withdrawn from the market.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here